ID   OV-MZ-6
AC   CVCL_4005
SY   OVMZ-6
DR   BTO; BTO_0004487
DR   Wikidata; Q54936868
RX   DOI=10.5282/edoc.3898;
RX   PubMed=1500230;
RX   PubMed=11242531;
RX   PubMed=15153938;
RX   PubMed=15706405;
RX   PubMed=21559638;
CC   Doubling time: 28 hours (PubMed=1500230).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 14
//
RX   DOI=10.5282/edoc.3898;
RA   Euer N.I.;
RT   "Identification of target genes for the therapy and diagnosis of
RT   ovarian carcinoma.";
RL   Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=1500230; DOI=10.1002/ijc.2910520115;
RA   Mobus V.J., Gerharz C.-D., Press U., Moll R., Beck T., Mellin W.,
RA   Pollow K., Knapstein P.-G., Kreienberg R.;
RT   "Morphological, immunohistochemical and biochemical characterization
RT   of 6 newly established human ovarian carcinoma cell lines.";
RL   Int. J. Cancer 52:76-84(1992).
//
RX   PubMed=11242531; DOI=10.1089/10430340150504019;
RA   Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J.,
RA   Kreienberg R., Runnebaum I.B.;
RT   "Adenoviral transduction efficiency of ovarian cancer cells can be
RT   limited by loss of integrin beta3 subunit expression and increased by
RT   reconstitution of integrin alphaVbeta3.";
RL   Hum. Gene Ther. 12:391-399(2001).
//
RX   PubMed=15153938; DOI=10.1038/sj.cgt.7700727;
RA   Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.;
RT   "Cooperative effect of adenoviral p53 gene therapy and standard
RT   chemotherapy in ovarian cancer cells independent of the endogenous p53
RT   status.";
RL   Cancer Gene Ther. 11:547-554(2004).
//
RX   PubMed=15706405; DOI=10.3892/or.13.3.375;
RA   Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R.,
RA   Weidle U.H.;
RT   "Identification of L1CAM, Jagged2 and neuromedin U as ovarian
RT   cancer-associated antigens.";
RL   Oncol. Rep. 13:375-387(2005).
//
RX   PubMed=21559638; DOI=10.3892/ijo.5.4.753;
RA   Will C., Wilhelm O.G., Hohl S., Mobus V.J., Weidle U.H., Kreienberg R.,
RA   Janicke F., Schmitt M., Graeff H.;
RT   "Expression of urokinase-type plasminogen-activator (uPA) and its
RT   receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion
RT   capacity.";
RL   Int. J. Oncol. 5:753-761(1994).
//